Royalty Pharma (RPRX) reported Q3 attributable net income of $145 million, down from $284 million a year earlier.
Total income and other revenue for the quarter ended Sept. 30 stood at $690 million, compared with $609 million a year earlier.
Analysts' estimates were unavailable for comparison.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments